Biomarin Pharmaceutical Inc., of San Rafael, Calif., reported a non-GAAP net loss of $27.2 million for the quarter, compared to a non-GAAP net loss of $25.4 million for the first quarter of last year. GAAP net loss was $85.1 million, or 53 cents per basic and diluted share, for the first quarter of 2016, compared to GAAP net loss of $67.5 million, or 43 cents per share, for the first quarter of 2015.